Shohreh Shahabi

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/43708/publications.pdf

Version: 2024-02-01

41 papers

990 citations

471509 17 h-index 30 g-index

41 all docs

41 docs citations

times ranked

41

1797 citing authors

#	Article	IF	Citations
1	Prognosis and treatment of uterine leiomyosarcoma: A National Cancer Database study. Gynecologic Oncology, 2017, 145, 61-70.	1.4	144
2	Association of Circulating Tumor Cell Status With Benefit of Radiotherapy and Survival in Early-Stage Breast Cancer. JAMA Oncology, 2018, 4, e180163.	7.1	105
3	Low-grade and high-grade endometrial stromal sarcoma: A National Cancer Database study. Gynecologic Oncology, 2017, 146, 254-262.	1.4	83
4	Ovarian granulosa cell tumor: A National Cancer Database study. Gynecologic Oncology, 2017, 146, 285-291.	1.4	74
5	Prognosis and treatment of positive peritoneal cytology inÂearly endometrial cancer: matched cohort analyses fromÂthe National Cancer Database. American Journal of Obstetrics and Gynecology, 2018, 218, 329.e1-329.e15.	1.3	61
6	Macrogenomic engineering via modulation of the scaling of chromatin packing density. Nature Biomedical Engineering, 2017, 1, 902-913.	22.5	47
7	Surgical wait time: A new health indicator in women with endometrial cancer. Gynecologic Oncology, 2016, 141, 511-515.	1.4	45
8	Survival of women with Mullerian adenosarcoma: A National Cancer Data Base study. Gynecologic Oncology, 2016, 143, 636-641.	1.4	44
9	The impact of international economic sanctions on Iranian cancer healthcare. Health Policy, 2015, 119, 1309-1318.	3.0	41
10	Chemotherapy delay after primary debulking surgery for ovarian cancer. Gynecologic Oncology, 2017, 144, 260-265.	1.4	36
11	21-Gene Recurrence Score Assay Predicts Benefit of Post-Mastectomy Radiotherapy in T1-2 N1 Breast Cancer. Clinical Cancer Research, 2018, 24, 3878-3887.	7.0	34
12	Association of chemotherapy and radiotherapy sequence with overall survival in locoregionally advanced endometrial cancer. Gynecologic Oncology, 2019, 153, 41-48.	1.4	29
13	Stage I uterine carcinosarcoma: Matched cohort analyses for lymphadenectomy, chemotherapy, and brachytherapy. Gynecologic Oncology, 2017, 145, 71-77.	1.4	24
14	Outcomes and costs of open, robotic, and laparoscopic radical hysterectomy for stage IB1 cervical cancer Journal of Clinical Oncology, 2018, 36, 5502-5502.	1.6	24
15	The selected biomarker analysis in 5 types of uterine smooth muscle tumors. Human Pathology, 2018, 76, 17-27.	2.0	21
16	Survival of patients with structurally-grouped TP53 mutations in ovarian and breast cancers. Oncotarget, 2015, 6, 18641-18652.	1.8	20
17	Survival after pelvic exenteration for uterine malignancy: A National Cancer Data Base study. Gynecologic Oncology, 2016, 143, 472-478.	1.4	19
18	Discovery of candidate tumor biomarkers for treatment with intraperitoneal chemotherapy for ovarian cancer. Scientific Reports, 2016, 6, 21591.	3.3	18

#	Article	lF	Citations
19	Feasibility and Preliminary Efficacy of a Bright Light Intervention in Ovarian and Endometrial Cancer Survivors. International Journal of Behavioral Medicine, 2021, 28, 83-95.	1.7	12
20	Association of increased primary breast tumor AGR2 with decreased disease-specific survival. Oncotarget, 2018, 9, 23114-23125.	1.8	11
21	Cost-effectiveness analysis of dose-dense versus standard intravenous chemotherapy for ovarian cancer: An economic analysis of results from the Gynecologic Oncology Group protocol 262 randomized controlled trial. Gynecologic Oncology, 2017, 145, 9-14.	1.4	10
22	The Hispanic Paradox in endometrial cancer: A National Cancer Database study. Gynecologic Oncology, 2017, 146, 351-358.	1.4	10
23	Survival Disparities by Hospital Volume Among American Women With Gynecologic Cancers. JCO Clinical Cancer Informatics, 2017, 1, 1-15.	2.1	10
24	How Can Pelvic MRI with Diffusion-Weighted Imaging Help My Pregnant Patient?. American Journal of Perinatology, 2020, 37, 577-588.	1.4	10
25	Transversus abdominis plane block with liposomal bupivacaine compared to oral opioids alone for acute postoperative pain after laparoscopic hysterectomy for early endometrial cancer: a cost-effectiveness analysis. Gynecologic Oncology Research and Practice, 2017, 4, 12.	3.6	7
26	Discussing sarcoma risks during informed consent for nonhysterectomy management of fibroids: anÂunmetÂneed. American Journal of Obstetrics and Gynecology, 2018, 218, 103.e1-103.e5.	1.3	7
27	Increased HE4 mRNA Expression Correlates with High Level Of elF3a mRNA And Better Survival in Women with Epithelial Ovarian Cancer. Journal of Cancer, 2018, 9, 1088-1095.	2.5	7
28	Urine Protein/Creatinine Ratios during Labor: A Prospective Observational Study. PLoS ONE, 2016, 11, e0160453.	2.5	7
29	Efficacy and safety of tivozanib in recurrent, platinum-resistant ovarian, fallopian tube or primary peritoneal cancer, an NCCN phase II trial. Gynecologic Oncology, 2021, 163, 57-63.	1.4	6
30	Further content validation of the 18-item NCCN/FACT Ovarian Symptom Index and its Disease Related Symptom-Physical (DRS-P) subscale for use in advanced ovarian cancer clinical trials. Health and Quality of Life Outcomes, 2019, 17, 185.	2.4	5
31	Delayed and clinically isolated port site carcinosarcoma recurrence as an early indicator of disseminated disease. Gynecologic Oncology Reports, 2015, 14, 12-15.	0.6	4
32	Metastatic Uterine Leiomyosarcoma Involving Bilateral Ovarian Stroma without Capsular Involvement Implies a Local Route of Hematogenous Dissemination. Case Reports in Obstetrics and Gynecology, 2015, 2015, 1-5.	0.3	4
33	HE4 and eIF3a Expression Correlates with Surgical Outcome and Overall Survival in Ovarian Cancer Patients with Secondary Cytoreduction. Journal of Cancer, 2018, 9, 2472-2479.	2.5	4
34	Efficacy and safety of tivozanib in recurrent, platinum-resistant ovarian, fallopian tube or primary peritoneal cancer Journal of Clinical Oncology, 2019, 37, 5538-5538.	1.6	3
35	Association of Lymph Node Count and Overall Survival in Node-Negative Endometrial Cancers. JCO Clinical Cancer Informatics, 2017, 1, 1-15.	2.1	1
36	Scholarship Support for Veterans Enrolling in MD, JD, and MBA Programs. JAMA - Journal of the American Medical Association, 2018, 320, 1197.	7.4	1

#	Article	IF	CITATIONS
37	Association between Cervical Dysplasia and Adverse Pregnancy Outcomes. American Journal of Perinatology, 2020, 37, 947-954.	1.4	1
38	Elimination of pelvic exams in a high-risk ovarian cancer screening program Journal of Clinical Oncology, 2016, 34, e13059-e13059.	1.6	1
39	Use of adjuvant chemotherapy and radiation in women with node-positive endometrial cancer: A National Cancer Database study Journal of Clinical Oncology, 2016, 34, 5588-5588.	1.6	O
40	Circulating tumor cell status and benefit of radiotherapy in stage I breast cancer Journal of Clinical Oncology, 2017, 35, 11524-11524.	1.6	0
41	Examining screening behaviors at a high-risk ovarian cancer clinic Journal of Clinical Oncology, 2017, 35, e13047-e13047.	1.6	0